Suppression of acetyl-CoA acetyltransferase 1 (ACAT1) responsible for cholesterol esterification or cholesterol transporter proprotein convertase subtilisin/kexin type 9 (PCSK9) improves the anti-tumor performance of CD8+ T cells and potentiates ICB therapy (Yang et al., 2016; Liu et al., 2020). Here, CD8A is linked to neoplasm.